Chikungunya is prevalent in Africa, South Asia, and South-East Asia and is transmitted by the Aedes mosquito, the same mosquito that spreads dengue fever. Singapore alone, over 1000 Chikungunya cases were reported over the period 2008-2010.Identify and generate fully human monoclonal antibodies, to develop two antibodies that could neutralize several Chikungunya strains in vitro by culturing immune cells from an individual who had developed resistance to Chikungunya. Monoclonal antibodies can be more potent and have fewer side effects than conventional small molecule drugs.
“The discovery of these antibodies is a big step forward in combating a disease that presently has no available vaccine or specific treatment. This was invaluable in helping to isolate the target antibodies from the cultured immune cells.Further validate the use of these antibodies as a viable treatment for Chikungunya.”Further testing in vivo would have to be carried out to validate the antibodies’ performance as a potential treatment for Chikungunya.
“The successful synergy is that the development of two antibodies against a disease that is on the rise has been accomplished. The human immunology, virology and molecular biology, helped to speed up the selection, sequencing and characterization of the most potent antibody candidates.To note that this breakthrough was achieved in less than a year from the start of the project”.
“The new platform used for the generation of fully human monoclonal antibody is already providing excellent results, and to generate a number of new fully human monoclonal antibodies that could be used as therapeutics.
"The discovery of these new fully human monoclonal antibodies with strong neutralizing activities against the Chikungunya virus constitutes an an additional testimony of the efficiency of the Humalex® platform.For more information contact coordinator [ a t ] nthrys -dot- com
No comments:
Post a Comment